 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Johnson & Johnson |
| Street 1: | One Johnson & Johnson Plaza |
| Street 2: | |
| City: | New Brunswick, NJ |
| Province: | |
| Post Code: | 08933 |
| Country: | United States of America |
| Phone: | +17325240400 |
| Organization Email: | jkallen1@its.jnj.com |
| Web Site: | http://www.jnj.com/global-public-health |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | None |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Organization Description: | |
| Johnson & Johnson Global Public Health is the first fully dedicated organization within a healthcare company that combines R&D, novel access programs & business model innovation, in-country operations, advocacy and the power of multisectoral partnerships to ensure that innovative treatments and technologies are available, affordable and accessible for the world's most underserved populations. Harnessing the extensive resources and expertise from across Johnson & Johnson, the Global Public Health team is accelerating the pace of innovation needed from discovery to delivery to make TB and HIV history, eliminate intestinal worms, address mental health and drive progress against other public health challenges. Johnson & Johnson has a longstanding commitment to combatting TB. When bedaquiline was introduced in December 2012, it was the first drug with a novel mechanism of action against TB in over 40 years. Since then, Johnson & Johnson has provided more than 58,500 courses of treatment to patients in need in over 100 countries, including through the Bedaquiline Donation Program. Beyond ensuring access to bedaquiline, the company is supporting high-burden countries to: • train health workers on the clinical management of TB; • ensure appropriate use of bedaquiline to prevent further resistance from developing; • improve diagnostic capacity; and • raise awareness and reduce stigma around TB at the community level. Johnson & Johnson is one of only a few pharmaceutical companies further investing significantly in research and development for the next-generation treatments that will be needed to reach the Sustainable Development Goal target and WHO End TB Strategy goal of ending TB by 2030. |
|
| Do you know about the UNHLM declaration: | |
Specializations / Areas of Work | |
|
Funding, including innovative and optimized approach to funding TB Care Provision of drugs, diagnostics and commodities Research and Development |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 26 - 50 |
| Number of part-time staff who are directly involved with TB: | 100 + |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | Other partners |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Network with other partners |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| tbd | |
Geographical Reach | |
| Which country is your headquarters located in: | United States of America |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
China India Indonesia Philippines South Africa Viet Nam |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | April 30, 2018 |
| Last updated: | June 25, 2018 |